About The Webinar
The new Section 232 tariffs on pharmaceuticals raise broader legal, compliance, and supply chain considerations for companies operating in this sector. This webinar will examine what these measures may mean for manufacturers, importers, and downstream market participants. Our speaker will discuss the practical challenges companies may face in assessing exposure, managing compliance risk, and planning for operational disruption, as well as what steps companies can take to respond.
Speaker

ANDREA K. JEGLUM is an associate with Sandler, Travis & Rosenberg, P.A., located in the Boston area. She concentrates her practice on customs compliance matters including tariff classification, country of origin, valuation, trade agreements, foreign-trade zones, and duty reduction programs. She also helps clients meet U.S. requirements concerning trade in biopharma, agro-chemicals, and animal products, including endangered species, as well as export filings and enforcement measures.
Key Topics
- Explanation of the new Section 232 tariffs on pharmaceuticals
- Key compliance and reporting considerations triggered by Section 232 trade actions
- Compliance considerations for companies navigating heightened trade and enforcement scrutiny
Related On Demand Webinars
-
On Demand
Learn MoreImport Compliance Bootcamp
Customs & Import Compliance -
On Demand
Learn MoreUnderstanding U.S. Customs Valuation in the Biopharma and Life Sciences Industry
Customs & Import Compliance -
On Demand
Learn MoreDetention and Seizure of Imported Merchandise
Forced Labor: Programs, Section 307 WROs & Detentions, Product Admissibility & Safety, IPR: Trademarks, Copyrights & Gray Market, Customs & Import Compliance